Rocky Mountain Advisers »

Crispr Therapeutics shares owned by Rocky Mountain Advisers

Quarter-by-quarter ownership of Crispr Therapeutics (CRSP) shares owned by Rocky Mountain Advisers from 13F filings

Historical chart of Rocky Mountain Advisers investment in Crispr Therapeutics

Tip: Access up to 7 years of quarterly data

All positions including Crispr Therapeutics held by Rocky Mountain Advisers consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Crispr Therapeutics by Rocky Mountain Advisers

Quarter filed Position value Share count Share price at filing
2025-09-30 $972 15 64.80

More positions owned by Rocky Mountain Advisers

Elevation Series Trust Srh Us Quality (SRHQ)
Elevation Series Trust Srh Reit Covered (SRHR)
Schwab Strategic Tr Us Dividend Eq (SCHD)
JPMorgan Chase & Co. (JPM)
Cohen & Steers infrastucture Fund (UTF)
Schwab Strategic Tr Us Brd Mkt Etf (SCHB)
Berkshire Hathaway Inc Del Cl B New (BRK.B)
American Centy Etf Tr Us Large Cap Vlu (AVLV)
Evercore Class A (EVR)
Boulder Growth & Income Fund (STEW)
Ishares Tr Core S&p500 Etf (IVV)
Vanguard Index Fds S&p 500 Etf Shs (VOO)
Microsoft Corporation (MSFT)
Vanguard Group Div App Etf (VIG)
Wal-Mart Stores (WMT)

View all positions for Rocky Mountain Advisers

Top funds holding Crispr Therapeutics

ARK Investment Management
BlackRock
Capital Research and Management Company - Division 3
Orbis Allan Gray
State Street Corporation
T. Rowe Price Investment Management
UBS Group
Vanguard Group
Sumitomo Mitsui Trust Holdings
Nikko Asset Management Americas
Geode Capital Management
Susquehanna International
Sr One Capital Management
Citadel Advisors
FMR

View all funds holding Crispr Therapeutics